Influenza Immunization

Infectious Diseases
1
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 1 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
2 programs
1
Fluzone Quadrivalent vaccine, No PreservativePhase 4Vaccine1 trial
Efluelda® Pre-filled syringeN/A1 trial
Active Trials
NCT07282795Not Yet Recruiting670Est. Mar 2029
NCT05050318Completed90Est. Nov 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
SanofiFluzone Quadrivalent vaccine, No Preservative
SanofiEfluelda® Pre-filled syringe

Clinical Trials (2)

Total enrollment: 760 patients across 2 trials

NCT05050318SanofiFluzone Quadrivalent vaccine, No Preservative

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Start: Sep 2021Est. completion: Nov 202190 patients
Phase 4Completed
NCT07282795SanofiEfluelda® Pre-filled syringe

Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe

Start: Mar 2026Est. completion: Mar 2029670 patients
N/ANot Yet Recruiting

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space